Shuttle Pharmaceuticals fails to meet Nasdaq filing requirements

Shuttle Pharmaceuticals, a company specializing in pharmaceutical software for molecular discovery and early-stage drug development, has been flagged for failing to meet Nasdaq filing requirements. The company missed the deadline for filing its quarterly report on Form 10-Q for the fiscal quarter ending June 30, 2026. They have assured that they plan to file the Form 10-Q as soon as feasible.

However, Shuttle Pharmaceuticals must submit a compliance plan to Nasdaq by October 27, 2026, explaining how it intends to regain compliance. Should Nasdaq approve the company's plan, it may grant an extension of up to 180 days, or until February 22, 2027, for the company to regain compliance. It's important to note that there's no guarantee Nasdaq will accept the compliance plan or that Shuttle Pharmaceuticals will regain compliance within the extension period.

The status of the company's listing on Nasdaq will be updated on September 4, 2026, and an indicator of its non-compliance will be broadcast over Nasdaq's market data dissemination network. If Shuttle Pharmaceuticals fails to regain compliance within the stipulated time, its common stock may be subject to delisting from Nasdaq.